MHRA-101378-PIP01-24

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • UPADACITINIB
Invented Name
Rinvoq
PIP Number MHRA-101378-PIP01-24
Pharmaceutical form(s)
  • Prolonged-release tablet
  • Age-appropriate oral liquid dosage form
Therapeutic area
Therapeutic area:
  • Dermatology
Conditions / Indications
Conditions / Indications:
  • Treatment of hidradenitis suppurativa
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):UPADACITINIB.pdf
Published Date 03/10/2024